D J Greenblatt, R I Shader. Show Affiliations »
Abstract
Entities: Chemical
Mesh: See more » Administration, OralAnti-Anxiety Agents/therapeutic useHalf-LifeHumansInjections, IntramuscularInjections, IntravenousLorazepam/administration & dosageLorazepam/adverse effectsLorazepam/therapeutic usePrazepam/administration & dosagePrazepam/adverse effectsPrazepam/metabolismPrazepam/therapeutic useSleep Initiation and Maintenance Disorders/drug therapy
Substances: See more » Anti-Anxiety AgentsLorazepamPrazepam
Year: 1978 PMID: 30899 DOI: 10.1056/NEJM197812142992405
Source DB: PubMed Journal: N Engl J Med ISSN: 0028-4793 Impact factor: 91.245